Outcomes in COVID-19 bebtelovimab studies
0
0.5
1
1.5+
ALL STUDIES
MORTALITY
HOSPITALIZATION
VIRAL CLEARANCE
RCTS
All
Early
Bebtelovimab for COVID-19
C19EARLY.COM/BT AUG 2022
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement All studies -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement 1 bebtelovimab COVID-19 study c19early.com/bt Aug 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement All studies -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement 1 bebtelovimab COVID-19 mortality result c19early.com/bt Aug 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.79
Early treatment -27%
1.27 [0.25-6.46]
5/252
2/128
-27% improvement All studies -27%
1.27 [0.25-6.46]
5/252
2/128
-27% improvement 1 bebtelovimab COVID-19 hospitalization result c19early.com/bt Aug 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.79
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement All studies -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement 1 bebtelovimab COVID-19 serious outcome c19early.com/bt Aug 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) 36%
0.64 [0.40-1.03]
viral+
33/252
26/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.066
Early treatment 36%
0.64 [0.40-1.03]
33/252
26/128
36% improvement All studies 36%
0.64 [0.40-1.03]
33/252
26/128
36% improvement 1 bebtelovimab COVID-19 viral clearance result c19early.com/bt Aug 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.066
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement All studies -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement 1 bebtelovimab COVID-19 Randomized Controlled Trials c19early.com/bt Aug 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement All studies -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement 1 bebtelovimab COVID-19 RCT mortality result c19early.com/bt Aug 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Lilly (RCT) -201%
3.01 [0.12-73.2]
death
1/127
0/128
Lilly (RCT) -27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Lilly (RCT) -51%
1.51 [0.26-8.90]
hosp.
3/127
2/128
Lilly (RCT) -2%
1.02 [0.15-7.16]
hosp.
2/125
2/128
Lilly (RCT) 36%
0.64 [0.40-1.03]
viral+
33/252
26/128
Lilly (RCT) 38%
0.62 [0.35-1.10]
viral+
16/127
26/128
Lilly (RCT) 33%
0.67 [0.38-1.17]
viral+
17/125
26/128
bebtelovimab COVID-19 outcomes c19early.com/bt Aug 2022
Favors bebtelovimab
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
